Breast Cancer Somatic Genetics Consortium. Genes Chromosomes Cancer 1999, 25:212–221.GSK2399872A concentration PubMedCrossRef 10. Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA: Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 1994, Pexidartinib chemical structure 54:4586–4589.PubMed 11. Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM: Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res
1994, 54:6270–6274.PubMed 12. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, van’t Veer LJ: The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 2008, 107:243–248.PubMedCrossRef 13. Swift M, Morrell D, Massey RB, Chase CL: Incidence of
cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991, 325:1831–1836.PubMedCrossRef 14. Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994, 66:S177–182.PubMedCrossRef 15. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF: Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 1999, 79:1304–1307.PubMedCrossRef 16. Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996, 92:130–134.PubMedCrossRef 17. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van’t Veer LJ: ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. FK228 cell line Am J Hum Genet 2000, 66:494–500.PubMedCrossRef 18. Milne RL: Variants
in the ATM gene and breast cancer susceptibility. Genome Medicine 2009., 1: 19. Mehdipour P, Mahdavi M, Mohammadi-Asl J, Atri M: Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer. Medical Oncology 2010, 1–5. 20. Gao LB, Pan Idoxuridine XM, Jia J, Liang WB, Rao L, Xue H, Zhu Y, Li SL, Lv ML, Deng W, Chen TY, Wei YG, Zhang L: IL-8 -251A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. Eur J Cancer 2010, 46:1333–1343.PubMedCrossRef 21. Gao LB, Bai P, Pan XM, Jia J, Li LJ, Liang WB, Tang M, Zhang LS, Wei YG, Zhang L: The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, in press. 22. Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, Wei YG, Tang M, Zhang L: RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 2010, in press. 23. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539–1558.PubMedCrossRef 24. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease.